DaVita (NYSE:DVA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of DaVita (NYSE:DVA) from a hold rating to a buy rating in a report released on Saturday,Wall Street Zen reports.

Several other research firms have also issued reports on DVA. Weiss Ratings upgraded shares of DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday, October 9th. Raymond James Financial set a $220.00 price objective on DaVita in a report on Friday, August 7th. TD Cowen raised DaVita from a “hold” rating to a “buy” rating and boosted their target price for the company from $201.00 to $220.00 in a research note on Friday, August 7th. Oppenheimer set a $220.00 target price on DaVita in a report on Friday, August 7th. Finally, Truist Financial dropped their target price on DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a report on Friday, August 7th. Four research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $233.43.

DaVita Stock Performance

DVA stock opened at $187.22 on Friday. The company has a market capitalization of $11.94 billion, a PE ratio of 15.32, a price-to-earnings-growth ratio of 0.49 and a beta of 0.80. DaVita has a one year low of $101.00 and a one year high of $247.49. The company’s 50 day moving average price is $180.54 and its two-hundred day moving average price is $191.07.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The company had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.50 billion. During the same quarter in the prior year, the company earned $2.95 EPS. The firm’s revenue was up 5.2% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, research analysts predict that DaVita will post 14.57 EPS for the current year.

Institutional Trading of DaVita

Several large investors have recently modified their holdings of the business. Value Investment Professionals LLC increased its position in DaVita by 2.0% during the 2nd quarter. Value Investment Professionals LLC now owns 2,501 shares of the company’s stock valued at $556,000 after purchasing an additional 50 shares during the period. Kesler Norman & Wride LLC raised its holdings in shares of DaVita by 0.8% in the 1st quarter. Kesler Norman & Wride LLC now owns 6,816 shares of the company’s stock valued at $1,048,000 after purchasing an additional 55 shares in the last quarter. State of Alaska Department of Revenue raised its holdings in shares of DaVita by 1.9% in the 3rd quarter. State of Alaska Department of Revenue now owns 3,206 shares of the company’s stock valued at $560,000 after purchasing an additional 60 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in shares of DaVita by 4.1% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,915 shares of the company’s stock worth $426,000 after purchasing an additional 76 shares during the period. Finally, CoreCap Advisors LLC lifted its position in shares of DaVita by 161.7% in the 3rd quarter. CoreCap Advisors LLC now owns 157 shares of the company’s stock worth $27,000 after purchasing an additional 97 shares during the period. 90.12% of the stock is owned by institutional investors.

About DaVita

DaVita Inc (NYSE: DVA) is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.